Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 14/20 | 0.60 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.54 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.54 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.54 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.51 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12737530 | 1.00 | ACHE (0.60) | ACHESIRT2SIRT1SIRT3EPHX1 | |
| SCHEMBL12193088 | 1.00 | ACHE (0.60) | ACHESIRT2SIRT1SIRT3EPHX1 | |
| SCHEMBL12193091 | 0.91 | SIRT2 (0.52) | ACHESIRT2SIRT1SIRT3EPHX1 | |
| SCHEMBL3699964 | 0.91 | ACHE (0.59) | ACHESIRT2SIRT1SIRT3EPHX1 | |
| SCHEMBL13148035 | 0.91 | ACHE (0.59) | ACHESIRT2SIRT1SIRT3EPHX1 | |
| SCHEMBL3695872 | 0.91 | ACHE (0.59) | ACHESIRT2SIRT1SIRT3EPHX1 | |
| SCHEMBL12737529 | 0.89 | ACHE (0.60) | ACHESIRT2SIRT1EPHX2 | |
| SCHEMBL12737546 | 0.89 | ACHE (0.60) | ACHESIRT2SIRT1EPHX2 | |
| SCHEMBL19651520 | 0.89 | ACHE (0.60) | ACHESIRT2SIRT1EPHX2 | |
| SCHEMBL12737514 | 0.89 | ACHE (0.50) | ACHESIRT2SIRT1SIRT3EPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10039864-B2 | Oligofluorinated cross-linked polymers and uses thereof | INTERFACE BIOLOGICS, INC. (CA) | 2018-08-07 | — | — | US | disclosed |
| US-20170340781-A1 | OLIGOFLUORINATED CROSS-LINKED POLYMERS AND USES THEREOF | Evonik Canada Inc. (CA) | 2017-11-30 | — | — | US | disclosed |
| US-20110091508-A1 | OLIGOFLUORINATED CROSS-LINKED POLYMERS AND USES THEREOF | Interface Biologics ,Inc. (CA) | 2011-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110091508-A1 | OLIGOFLUORINATED CROSS-LINKED POLYMERS AND USES THEREOF | MACF1, PUF60, PFAS | ACHE 3699/4885SIRT2 2740/4885SIRT1 3457/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.